862583-15-1|Gastrazole sodium|sodium (S)-5-(2-(6-(cycloheptyl(methyl)carbamoyl)-1H-benzo[d]imidazole-5-carboxamido)-3-(2-fluorophenyl)propanamido)isophthalate|-范德生物科技公司

Gastrazole sodium

NMR下载 COA and HPLC MSDS下载
names：
sodium (S)-5-(2-(6-(cycloheptyl(methyl)carbamoyl)-1H-benzo[d]imidazole-5-carboxamido)-3-(2-fluorophenyl)propanamido)isophthalate
CAS号：
862583-15-1
MDL Number：
MF(分子式)： C34H32FN5Na2O7 MW(分子量)： 687.64
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Gastrazole sodium
英文别名	Gastrazole; Gastrazole sodium; JB-95008; JB95008; JB 95008
CAS号	862583-15-1
SMILES	O=C(C1=CC(NC([C@@H](NC(C2=C(C(N(C3CCCCCC3)C)=O)C=C4C(N=CN4)=C2)=O)CC5=CC=CC=C5F)=O)=CC(C([O-])=O)=C1)[O-].[Na+].[Na+]
Inchi	InChI=1S/C34H34FN5O7.2Na/c1-40(23-9-4-2-3-5-10-23)32(43)25-17-28-27(36-18-37-28)16-24(25)30(41)39-29(15-19-8-6-7-11-26(19)35)31(42)38-22-13-20(33(44)45)12-21(14-22)34(46)47;;/h6-8,11-14,16-18,23,29H,2-5,9-10,15H2,1H3,(H,36,37)(H,38,42)(H,39,41)(H,44,45)(H,46,47);;/q;2*+1/p-2/t29-;;/m0../s1
InchiKey	OHDLJFNGLVCFIN-UJXPALLWSA-L
分子式 Formula	C34H32FN5Na2O7
分子量 Molecular Weight	687.64
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Gastrazole sodium(CAS:862583-15-1):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Gastrazole, also know as JB-95008, is a CCK2 receptor antagonist potentially for the treatment of pancreatic cancer.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Harper EA, Mitchell EA, Griffin EP, Kalindjian SB. Thermodynamic analysis does not allow discrimination of agonists and antagonists at human CCK2S-receptors. Eur J Pharmacol. 2008 Feb 26;581(1-2):1-12. PubMed PMID: 18158148.

[2]Harper EA, Roberts SP, Kalindjian SB. Thermodynamic analysis of ligands at cholecystokinin CCK2 receptors in rat cerebral cortex. Br J Pharmacol. 2007 Aug;151(8):1352-67. PubMed PMID: 17592503; PubMed Central PMCID: PMC2189820.

[3] Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, HarrisonP, Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, Theis B, Hull R, Walker M, Shankley N, Kalindjian B, Murray G, Gillbanks A, Black J. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 Apr 24;94(8):1107-15. PubMed PMID: 16622436; PubMed Central PMCID: PMC2361246.

[4] Clarke PA, Dickson JH, Harris JC, Grabowska A, Watson SA. Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor. Cancer Res. 2006 Apr 1;66(7):3504-12. PubMed PMID: 16585174.

[5] Buck IM, Black JW, Cooke T, Dunstone DJ, Gaffen JD, Griffin EP, Harper EA, Hull RA, Kalindjian SB, Lilley EJ, Linney ID, Low CM, McDonald IM, Pether MJ, Roberts SP, Shankley NP, Shaxted ME, Steel KI, Sykes DA, Tozer MJ, Watt GF, Walker MK, Wright L, Wright PT. Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists. J Med Chem. 2005 Nov 3;48(22):6803-12. PubMed PMID: 16250639.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开